Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Recruiting
- Conditions
- Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
- Interventions
- Other: Non-investigational
- First Posted Date
- 2023-05-22
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT05868629
- Locations
- 🇺🇸
Johns Hopkins University, Washington, District of Columbia, United States
🇺🇸Duke Clinical Research Institute, Durham, North Carolina, United States
🇺🇸Oncology Hematology Care Inc, Cincinnati, Ohio, United States
Examining the Clinical Characteristics, Treatment Patterns, Real-world Effectiveness, and Healthcare Resource Utilization of Patients With Dry Eye Disease
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Registration Number
- NCT05857748
Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT05853458
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerselen, Germany
A Descriptive Study of Baseline Characteristics, Clinical Outcomes, and Treatment Patterns of HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Alpelisib Plus Fulvestrant Who Have Received Fulvestrant in Any Prior Line of Therapy
Completed
- Conditions
- HR+/HER2- Advanced or Metastatic Breast Cancer
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 157
- Registration Number
- NCT05853432
- Locations
- 🇮🇪
Novartis Pharmaceuticals, Dublin, Ireland
A Prospective, Non-interventional Study of JAKAVI® (Ruxolitinib) Treatment in Patients With Polycythemia Vera
Completed
- Conditions
- Polycythemia Vera
- Interventions
- Other: Jakavi
- First Posted Date
- 2023-05-10
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 467
- Registration Number
- NCT05853445
- Locations
- 🇩🇪
Novartis Investigative Site, Wuerzburg, Germany
Healthcare Resource Utilization and Costs in Metastatic Melanoma Patients Initiated Dabrafenib + Trametinib and Encorafenib + Binimetinib
Terminated
- Conditions
- Metastatic Melanoma
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 543
- Registration Number
- NCT05848219
- Locations
- 🇺🇸
Novartis Investigational Site, East Hanover, New Jersey, United States
Impact of Formulary Coverage of Entresto (Sacubitril/Valsartan) on Prescription Abandonment/Rejection and Subsequent Treatment and Economic Outcomes in Chronic Heart Failure Patients in the U.S.
Completed
- Conditions
- Chronic Heart Failure
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2023-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 251831
- Registration Number
- NCT05848206
- Locations
- 🇺🇸
IQVIA, Durham, North Carolina, United States
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Phase 2
Recruiting
- Conditions
- Prostatic Neoplasm
- Interventions
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT05849298
- Locations
- 🇺🇸
Urology Associates of Mobile, Mobile, Alabama, United States
🇺🇸Rocky Mountain Cancer Centers, Longmont, Colorado, United States
🇺🇸University Cancer and Blood Center LLC, Athens, Georgia, United States
LUTATHERA Injection General Use Result Survey
Completed
- Conditions
- Somatostatin Receptor-positive Neuroendocrine Tumor
- Interventions
- Other: LUTATHERA
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 347
- Registration Number
- NCT05844332
- Locations
- 🇯🇵
Novartis Investigative Site, Yamagata, Japan
Efficacy, Safety and Tolerability of KLU156 in Adults and Children ≥ 5 kg Body Weight With Uncomplicated P. Falciparum Malaria
Phase 3
Recruiting
- Conditions
- Uncomplicated Plasmodium Falciparum Malaria
- Interventions
- First Posted Date
- 2023-05-06
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1500
- Registration Number
- NCT05842954
- Locations
- 🇿🇲
Novartis Investigative Site, Ndola, Zambia
© Copyright 2025. All Rights Reserved by MedPath